1
2
3
Makady, Amr, van Acker, Sandine, Nijmeijer, Hugo, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf, Goettsch, Wim
Veröffentlicht in: Makady , A , van Acker , S , Nijmeijer , H , de Boer , A , Hillege , H , Klungel , O & Goettsch , W 2019 , ' Conditional Financing of Drugs in the Netherlands : Past, Present, and Future-Results From Stakeholder Interviews ' , Value in Health , vol. 22 , no. 4 , pp. 399-407 . https://doi.org/10.1016/j.jval.2018.11.016;
2019
Veröffentlicht in: Makady , A , van Acker , S , Nijmeijer , H , de Boer , A , Hillege , H , Klungel , O & Goettsch , W 2019 , ' Conditional Financing of Drugs in the Netherlands : Past, Present, and Future-Results From Stakeholder Interviews ' , Value in Health , vol. 22 , no. 4 , pp. 399-407 . https://doi.org/10.1016/j.jval.2018.11.016;
2019
4
5
6
7
8
Broekhoff, Thomas F., Sweegers, Carly C.G., Krijkamp, Eline M., Mantel-Teeuwisse, Aukje K., Leufkens, Hubert G.M., Goettsch, Wim G., Vreman, Rick A.
Veröffentlicht in: Broekhoff , T F , Sweegers , C C G , Krijkamp , E M , Mantel-Teeuwisse , A K , Leufkens , H G M , Goettsch , W G & Vreman , R A 2021 , ' Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios ' , Value in Health , vol. 24 , no. 6 , pp. 759-769 . https://doi.org/10.1016/j.jval.2020.09.021;
2021
Veröffentlicht in: Broekhoff , T F , Sweegers , C C G , Krijkamp , E M , Mantel-Teeuwisse , A K , Leufkens , H G M , Goettsch , W G & Vreman , R A 2021 , ' Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios ' , Value in Health , vol. 24 , no. 6 , pp. 759-769 . https://doi.org/10.1016/j.jval.2020.09.021;
2021